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Core-in-cup/liquisol dual tackling effect on azelnidipine 
buccoadhesive tablet micromeritics, in vitro release, 
and mucoadhesive strength
Reduced bioavailability of azelnidipine is related to its poor 
aqueous solubility and extensive first-pass metabolism, which 
hinder its efficacy. These problems were addressed by imple-
menting (1) a liquisol technique for promoting the dissolution 
rate in a controlled-release manner and (2) a core-in-cup bucco-
adhesive drug delivery system as an alternative to the oral 
route. A 33 factorial design was used to study the effects of 
polymer type (sodium carboxymethyl cellulose (CMC Na), 
chitosan, or Carbomer P940) concentration (5, 10 or 15 %) and 
preparation technique (simple mix, liquisol or wet granula-
tion) on the dissolution and mucoadhesion of core-in-cup 
azelnidipine buccoadhesive tablets. Tablet micromeritics, 
swelling index, mucoadhesive strength and in vitro release 
were characterized. Statistical analyses of these factors show ed 
significant effects on the studied responses, where F#16 
 prepared by the liquisol technique and containing 15 % CMC 
Na was chosen with an overall desirability of 0.953.
Keywords: azelnidipine, liquisol, core-in-cup, buccoadhesive 
tablets, tablet micromeritics, in vitro release
Azelnidipine (AZL), a dihydropyridine calcium channel blocker, stimulates periphe ral 
vasodilation by blocking calcium channels in vascular smooth muscle cells without increasing 
the heart rate. Poor bioavailability of AZL, which has the biopharmaceutics classification 
system (BCS) rating of class II and the molecular weight 582.65, is related to its poor aqueous 
solubility (less than 1 mg mL–1) and high lipophilicity partition coefficient (log P = 7, octa-
nol/Sorensen’s buffer pH 7.4) (1, 2). Moreover, AZL undergoes extensive first-pass meta-
bolism by cytochrome P450 (1), which hinders its efficacy in pharmaceutics. Conventional 
drug delivery has some limitations, viz., increased chances of missing the drug dose when 
frequent administration is necessary and an atypical plasma concentration time profile 
making it difficult to attain a steady state.
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Accordingly, these problems have been addressed using the liquisol technique, pri-
marily to enhance the solubility and promote the dissolution rate of AZL. First, the drug 
is solubilized in suitable solvents before being converted into free-flowing compressible 
powdered mixtures by blending with the selected carrier and coating materials (3). Sec-
ond, core-in-cup (CIC) buccoadhesive drug delivery is used as an alternative to the oral 
route to bypass AZL first-pass metabolism. CIC offers a safe and easy method for drug 
utilization, since the drug action can be promptly terminated by removing the CIC bucco-
adhesive tablet from the buccal cavity. This technique aims to control AZL release in a 
zero-order manner, ensuring unidirectional release and maintaining plasma concentra-
tions within the therapeutic window (4) to maintain normal blood pressure levels. These 
two methodologies were chosen for their ease in scaling up and hence their suitability for 
commercial production.
Thus, this research studied the factors affecting both tablet mucoadhesion (to ensure 
full-time contact with the buccal mucosa) and in vitro drug release. A buccoadhesive drug 




AZL was purchased from (Zhejiang Gaobang Pharmaceutical Co. Ltd., China), carboxy-
methylcellulose sodium 50–200 mPa s was purchased from (CP Kelco, USA). High-MW 
chitosan (310000–375000 Da) was purchased from (Sinochem Jiangsu, China). Carbomer 
P940 was purchased from (Aqualon, USA); Poloxamer 188 was purchased from (BASF, 
Germany); and Labrasol® and Transcutol® HP were kind gifts from (Gattefosse, Saint-Priest, 
France). Cremophor® RH40 was kindly provided by (BASF SE, Carl-Bosch, Germany). Poly-
ethylene glycol 6000 was procured from (El-Nasr Pharmaceutical Chemicals Co., Egypt). 
Mannitol was purchased from (Shandong Bangye Co. Ltd., China), ethyl cellulose was 
purchased from (FMC Biopolymer, Belgium), and magnesium stearate was purchased 
from (Aceto-Corp, USA). Sorenson phosphate buffer components (sodium phosphate dibasic 
anhydrous and sodium dihydrogen orthophosphate dihydrate) were purchased from 
(Loba Chemie, India). Aeropril 300 was obtained from (Degussa Ltd., Germany), high-
-performance liquid chromatography (HPLC)-grade acetonitrile was purchased from 
(Merck, Germany), and HPLC-grade methanol was purchased from (Fisher Scientific, UK). 
All other reagents were of analytical grade.
High-performance liquid chromatography (HPLC) analyses
AZL was quantified via a validated liquid chromatographic method using a Schi-
madzu instrument (UFLC Prominence 20 XR) with a UV detector for linearity, accuracy, 
selectivity and precision (5). A Thermo C18 column (5 µm; 4.6 × 150 mm) was used, and the 
mobile phase was a mixture of (acetonitrile/methanol/water, 2:2:1) (V/V), which was filtered, 
degassed and eluted at a flow rate of 2 mL min–1. Elution was detected at 260 nm, and the 
injection volume was 20 µL.
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Preformulation studies
Differential scanning calorimetry (DSC)
DSC was performed on the AZL, excipients and their 1:1 (m/m) physical mixtures 
(PMs). The excipients tested were carboxymethylcellulose sodium (CMC Na), chitosan, Car-
bomer P940, mannitol, Aeropril 300, and ethyl cellulose. DSC analysis was performed using 
a differential scanning calorimeter (DSC-60, Shimadzu, Japan). Samples (3–4 mg) were 
placed in aluminium pans and heated to 10–400 °C at a rate of 10 °C min–1, with indium in 
the reference pan under a nitrogenous atmosphere. DSC was used to determine any pos-
sible physicochemical interactions between the drug entity and the excipient used in its 
formulation.
Fourier transform infrared spectroscopy (FTIR)
FTIR spectra of 450–4000 cm–1 of the drug, excipients and their 1:1 (m/m) PMs were 
determined using an infrared spectrophotometer (Fourier Transform, FTIR-84005, Shi-
madzu) and the potassium bromide disk technique (6).
Screening the effects of different solubilizers on AZL solubility
Equilibrium solubility of AZL was studied by preparing the PMs of AZL with five 
solubilizers (Poloxamer 188, Cremophore RH40, Transcutol HP, Labrasol, and PEG 6000) at 
three ratios (1:1, 1:3 and 1:5, m/m). The PMs were prepared by mixing 25 mg of the drug with 
each solubilizer for 2 min to obtain homogeneous mixtures. To determine the solubility of 
AZL in these mixtures, each PM was shaken with 25 mL distilled water in an amber-
-colored glass vial, and the blank was 25 mg of the drug with 25 mL water only. The PMs 
were then left in a shaker at room temperature (25 °C) for 24 h. The samples were with-
drawn, filtered and analyzed using the previously described HPLC method.
Applying a 33 full factorial design for buccoadhesive tablets
Three factors were studied (the mucoadhesive polymer type, the polymer concentration 
and the preparation technique) to evaluate their influence on drug dissolution and muco-
adhesion. A 33 full factorial design was conducted yielding twenty-seven randomly performed 
AZL formulations. The factors studied with their respective levels and constraints are shown 
in Table I. The choice of factors and their respective levels was based on a literature review, 
field experience and preliminary studies conducted before implementing the experiment. 
Other variables, such as drug amount, solubilizer type (Poloxamer 188), carrier type (man-
nitol) and coating material (Aeropril 300) were kept constant. The responses measured were 
in vitro drug release after 2 h (Q2), 4 h (Q4), and 8 h (Q8) and mucoadhesive strength. 
Design-Expert software (V. 7.0.0, Stat-Ease Inc., USA) was used to apply and evaluate 
the factorial design. Means were compared by a factorial analysis of variance (ANOVA). 
The significance level was set at a = 0.05. Numerical optimization was performed using a 
statistical program per the constraints listed in Table I. The simultaneous optimization 
technique, based on the use of desirability functions, was chosen to optimize the responses. 
All experiments and characterizations were performed at least three times. All data are 
presented as the mean ± standard deviation.
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Preparation of core-in-cup (CIC) buccoadhesive tablets
Core preparation
Detailed composition of all formulations is shown in Table II. All formulations con-
tained 8 mg AZL. Three mucoadhesive polymers (CMC Na, chitosan and Carbomer P940) 
were studied at three ratios (5, 10 and 15 %). Three techniques were used to prepare the 
core powder mixture.
Simple mix technique (SM). – Calculated amounts of the drug, mucoadhesive polymer, 
Poloxamer 188, Aeropril 300, and mannitol were separately sieved using a sieve with 710-
µm pores. The powders were mixed using a mortar and pestle to form a dry powder mix-
ture.
Liquisol technique (LS). – Poloxamer 188 (24 mg) was melted at 55 °C, then 8 mg AZL 
was added (AZL/Poloxamer 188, 1:3, m/m) and stirred until the AZL completely dissolved 
in Poloxamer 188. Mannitol was added geometrically to improve the effective surface area 
for dissolution and to assist the compression. Next, the coating material (Aeropril 300) was 
added to improve the flowability, absorb excess liquid and give a dry appearance by cover-
ing wet carrier particles. Predetermined mucoadhesive polymer concentrations were then 
added to the mixture. Excipients were then geometrically mixed in a mortar for 20 min, 
and the final mixture was sieved using a sieve with 710-µm pores.
Wet granulation technique (WG). – AZL, the polymer, Aeropril 300, and mannitol were 
mixed using a mortar and pestle for 20 min to form a powder mixture. The granulating 
solution was prepared by dissolving Poloxamer 188 in 95 % ethanol at twice its weight. The 
powder mixture was granulated with the previously prepared solution and then sieved 
through a sieve with 850-µm pores. The granules were dried in an oven at 50 °C until the 
moisture content of bulk granules reached 2–3 % and then sieved using a sieve with 710-
µm pores to form a dry powder mixture. Moisture content was measured using a moisture 
analyzer (Schimadzu MOC-120HEXP).
Table I. 33 full factorial design: factors and responses
Factors (independent variables) Levels
A: Type of mucoadhesive polymer CMC Na Chitosan Carbomer P940
B: Concentration of mucoadhesive polymer 5 % 10 % 15 %
C: Technique of core preparation Simple mix Liquisol Wet granulation
Responses (Dependent variables) Constraintsa
R1: % drug released from the tablet after 2 h (Q2 %) 30 % ³ R1 ³ 20 %
R2: % drug released from the tablet after 4 h (Q4 %) 60 % ³ R2 ³ 40 %
R3: % drug released from the tablet after 8 h (Q8 %) R3 ³ 80 %
R4: Mucoadhesive strength (g) Maximize
a Constraints were set according to the international guidelines (9).
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After that, 1 % Mg stearate was mixed with each of the prepared dry powder mixtures 
for 2 min; these mixtures were then compressed into a 150-mg core using a single-punch 
tablet machine (KORSCH XP1) with a 7-mm diameter.
CIC preparation
Each precompressed core was placed separately in the center of a 9.5-mm punch, then 
the turret was lowered, and the cup layer (50 mg ethyl cellulose) was added to the die 











Q2 (%)  Q4 (%) Q8 (%)
Mucoadhesion 
strength (g)
A B C R1 R2 R3 R4
F#1 CMC Na 5 SM 19.85 ± 2.12 29.54 ± 2.11 52.29 ± 1.4 30.23 ± 1.33
F#2 chitosan 5 SM 11.84 ± 3.12 23.97 ± 5.12 40.78 ± 2.55 40.23 ± 1.44
F#3 Carbomer 5 SM 8.13 ± 2.48 14.59 ± 3.98 30.6 ± 2.22 31.23 ± 1.33
F#4 CMC Na 10 SM 10.76 ± 1.44 24.12 ± 3.97 48.32 ± 3.11 35.67 ± 2.04
F#5 chitosan 10 SM 7.74 ± 3.08 19.92 ± 4.22 34.43 ± 2.08 44.18 ± 2.63
F#6 Carbomer 10 SM 6.56 ± 4.11 12.11 ± 2.44 26.2 ± 3.55 35.56 ± 1.93
F#7 CMC Na 15 SM 8.04 ± 4.12 22.83 ± 3.38 42.12 ± 2.56 41.73 ± 1.67
F#8 chitosan 15 SM 4.02 ± 3.18 10.23 ± 4.34 29.23 ± 3.66 48.99 ± 1.87
F#9 Carbomer 15 SM 4.83 ± 4.21 9.23 ± 3.68 23.7 ± 3.67 41.11 ± 2.06
F#10 CMC Na 5 LS 60.86 ± 2.77 74.74 ± 2.4 95.09 ± 3.23 40.67 ± 2.45
F#11 chitosan 5 LS 57.56 ± 2.87 70.71 ± 2.98 87.76 ± 3.9 27.67 ± 2.17
F#12 Carbomer 5 LS 10.46 ± 4.37 23.56 ± 4.54 46.74 ± 2.55 30.22 ± 2,64
F#13 CMC Na 10 LS 45.99 ± 3.49 69.99 ± 2.44 88.79 ± 4.41 49.3 ± 0.59
F#14 chitosan 10 LS 31.08 ± 3.91 61.43 ± 2.5 79.87 ± 4.22 30.1 ± 1.77
F#15 Carbomer 10 LS 8.23  ± 3.44 16.23 ± 3.69 40.49 ± 5.07 35.2 ± 2.15
F#16 CMC Na 15 LS 24.57 ± 2.54 58.44 ± 4.57 85.44 ± 3.97 54.33 ± 2.43
F#17 chitosan 15 LS 28.26 ± 2.43 56.44 ± 3.02 76.37 ± 1.66 32.14 ± 1.58
F#18 Carbomer 15 LS 6.33 ± 4.32 13.4 ± 3.38 37.94 ± 3.88 41 ± 1.78
F#19 CMC Na 5 WG 47.45 ± 1.77 81.56 ± 3.55 98.3 ± 4.11 29.45 ± 1.77
F#20 chitosan 5 WG 60.74 ± 1.55 75.91 ± 2.58 95.33 ± 2.53 30.12 ± 2.54
F#21 Carbomer 5 WG 14.57 ± 3.43 26.36 ± 1.69 50.89 ± 4.37 33.29 ± 1.43
F#22 CMC Na 10 WG 42.45 ± 3.14 75.45 ± 2.69 94.56 ± 3.11 30.87 ± 1.34
F#23 chitosan 10 WG 46.78 ± 2.42 65.74 ± 2.69 86.78 ± 1.99 33.23 ± 2.24
F#24 Carbomer 10 WG 10.23 ± 4.21 18.92 ± 5.02 43.33 ± 4.48 34.54 ± 2.4
F#25 CMC Na 15 WG 38.4 ± 4.26 70.37 ± 3.22 90.84 ± 3.76 33.8 ± 0.98
F#26 chitosan 15 WG 38.77 ± 2.58 60.42 ± 1.97 81.37 ± 3.23 35.9 ± 1.39
F#27 Carbomer 15 WG 8.33 ± 3.44 15.44 ± 4.13 39.76 ± 4.11 35.17 ± 2.05
a Mean ± SD (n = 6), b SM – simple mix, LS – liquisol, WG – wet granulation.
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containing the core and compressed again to attain CIC-AZL buccoadhesive tablets (Fig. 
S1 in Supplementary Material).
Micromeritic formulation properties
Precompression flow properties and compressibility of the CIC-AZL buccoadhesive 
tablets (including flowability, angle of repose, bulk density, tapped density, Carr’s index 
and Hausner’s ratio) were determined for AZL and blended powders of all the cores before 
compression (6).
Characterizing the CIC-AZL buccoadhesive tablets
Swelling index. – To determine the swelling index (SI) of CIC-AZL buccoadhesive tab-
lets, the tablets were weighed individually (m0) and placed separately in Petri dishes con-
taining distilled water at pH 6.4 (n = 3). Tablets were removed from the Petri dish each hour 
for 6 h, and excess surface water was wiped carefully using filter paper. The swollen tablet 










Mucoadhesive strength. – Bioadhesive forces of the prepared CIC-AZL buccoadhesive 
tablets were measured according to Kassem et al. (8). Briefly, freshly excised bovine buccal 
mucosa (obtained from a local slaughterhouse and stored in normal saline at 4 °C upon 
collection), were fixed on glass stages using cyanoacrylate adhesive. Prepared tablets were 
attached to the balance pan, and the glass stage was raised slowly until the tablet surface 
contacted the buccal mucosa. A preload of 50 g was applied over the balance pan above the 
tablet for 5 min to establish adhesion bonding between the tablet and buccal mucosa and 
was then removed. The preload weight and time were kept constant for all formulations. 
Increasing weights were applied until the tablet detached from the buccal mucosa. Mini-
mum weight (in g) that detached the tablet from the membrane surface was recorded as a 
measure of mucoadhesive strength.
In vitro release study. – AZL release was performed using the USP Dissolution Tester, 
Apparatus II (rotating paddle, Erweka DT-700, Germany) at a rotation of 50 rpm. Experi-
ments were carried out at 37 ± 0.5 °C in 900 mL of Sorenson phosphate buffer (pH 6.8; USP), 
containing 1 % Tween-80 as surfactant. The cup layer of the buccoadhesive tablet was at-
tached to a glass disk using cyanoacrylate adhesive. The disk was placed at the bottom of 
the dissolution vessel. Samples were taken every hour for 8 h, then filtered and analyzed 
for AZL content by the previously mentioned HPLC method. The dissolution test was 
performed using six tablets per formula (Fig. S2 in Supplementary Material).
Three time points were included in the in vitro dissolution specifications of the con-
trolled-release tablets: an early time point to exclude dose dumping and/or characterize the 
initial dose (Q2 = 20–30 % dissolved), a second time point to ensure compliance with the 
dissolution profile shape (Q4 = 40–60 % dissolved) and a final time point to ensure that 
most of the drug was released (Q8 = more than 85 % dissolved) (9).
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Kinetic analysis of release data
Release profiles were analyzed using the zero-order, first-order and Higuchi’s square-
root equations (10, 11). The Hixson-Crowell model was also obtained to describe the re-
lease from systems with changes in the surface area and particle or tablet diameter (12).
Ex vivo permeation study
AZL permeation from the optimized formula (F#16, chosen by the factorial design) 
through bovine buccal mucosa (freshly excised bovine buccal mucosa, 0.3-cm thick, obtained 
from a local slaughterhouse and stored in normal saline at 4 °C upon collection after remov-
ing all fat and debris) was performed in triplicate using glass tubes opened from both sides 
with a 1.2-cm diameter. Each tablet was pressed on the mucosa for 30 seconds from the core 
side, and the tablet-loaded mucosa was stretched over an open end of the glass tube to form 
the donor chamber. Phosphate buffer (4 mL, pH 6.8) was added to the donor chamber. The 
tube was suspended on the side of the dissolution apparatus vessel so that the mucosa was 
just below the surface of 900 mL of phosphate buffer (pH 6.8) and was stirred at 50 rpm at 37 
± 0.5 °C, with a diffusional surface area of 1.13 cm2. Five-milliliter samples were removed at 
set time intervals and replaced by equivalent amounts of fresh phosphate buffer (pH 6.8). 
Permeated drug amounts were assayed using the previously described HPLC method.
RESULTS AND DISCUSSION
High-performance liquid chromatography (HPLC) analyses
Linearity was obeyed over a concentration range. The regression equation was com-
puted, and the R2 value was 0.998. Relative standard deviations of the AZL solution con-
centrations were all below 2 %.
Preformulation studies
Differential scanning calorimetry (DSC). – The DSC thermogram of AZL showed a char-
acteristic sharp melting endothermic peak at 123.6 °C, corresponding to the drug melting 
point. The DSC thermograms (in Supplementary Fig. S3) show the effect of mixing AZL 
with different excipients on the phase transition of the drug. Under experimental condi-
tions, for all selected excipients, the observed endothermic peak in the physical mixture 
was similar to the peak of the drug. This indicates that the crystalline form of AZL, but not 
its physical form, exists in the physical mixture, indicating excipient incompatibility.
Fourier transform infrared spectroscopy (FTIR). – The infrared spectrum of AZL showed 
a band at 1069 cm–1 due to a C-N primary amine stretch, a band at 1101 cm–1 due to a sec-
ondary alcohol C-O stretch, a band at 1486 cm-1 due to an aromatic ring stretch C=C-C 
bond, a band at 1652 cm–1 due to an aromatic nitro-oxy group and a band at 3315 cm–1 due 
to an aliphatic primary amine N-H stretch. The IR spectrum and PMs of AZL are shown 
in Supplementary Fig. S4. All AZL bands were preserved at the same positions, indicating 
that no interaction occurred between the drug and any of previous excipients. 
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Screening the effects of different solubilizers on AZL solubility
Equilibrium solubilities of the AZL PMs in distilled water are shown in Table III. Effects 
of solubilizers on the solubility were improved by increasing their concentrations. The PMs 
of the AZL/Poloxamer 188 (1:1, 1:3, and 1:5, m/m) had the highest AZL solubilities, increasing 
from 1.4 µg mL–1 (pure AZL) to 49.3, 56.7, and 56.7 µg mL–1, respectively. These results were 
attributed to the wetting, solubilizing, and surface activity of Poloxamer 188. PMs with the 
other solubilizers increased slightly the solubility of AZL, which may have been due to their 
limited wetting and solubilizing properties. Thus, the AZL/Poloxamer 188 at a ratio of 1:3 
was chosen for further investigation. Poloxamer 188 was also selected because of (1) its solid 
nature, which enabled the direct compression technique for the required tablets; (2) its low 
melting point (mp = 55 °C), which allowed the application of the liquisol technique; and (3) 
its solubility in 95 % ethanol, which allowed application of the wet granulation technique. 
Applying a 33 full factorial design for buccoadhesive tablets
The factorial design results are shown via prepared tablet characterizations. Statistical 
significance of the effects of the factors on the studied responses and their interactions is 
described.
Micromeritic formulation properties
Table IV shows the micromeritic formulation results. Formulations prepared using 
wet granulation showed good flowability, likely due to the change in particle size (13), 
Table III. Effect of different solubilizers on the equilibrium solubility of AZL in distilled water
Types of solubilizer Drug/solubilizer ratio Solubility (µg mL–1)
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while those prepared with the liquisol and simple mix techniques had reasonable flows. 
Carr’s index determination revealed that all formulations prepared using the wet granula-
tion and liquisol techniques had good flow, while those prepared with the simple mix 
technique showed fair flow. For the Hausner’s ratio values, most formulations, except F#9, 
had values of approximately 1.2, indicating low interparticle friction. This may have been 
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due to the presence of Carbomer at a high concentration (15 %) in the simple mix technique, 
which gave poor flowability to the bulk. The results showed that Carr’s index and Haus-
ner’s ratio increased as the polymer concentration increased, leading to poor flowability 
and compressibility. Hausner’s ratio results correlated well with the Carr’s index results, 
angle of repose, and flowability.
Characterization of CIC-AZL buccoadhesive tablets and statistical analyses
Swelling index
Buccoadhesive tablets require appropriate swelling behaviour for prolonged drug release 
and effective mucoadhesion. Being hydrogels, polymers swell readily when they contact a 
hydrated mucous membrane. Upon hydrating the tablets, the cores swelled with no change 
in cup appearance. Fig. 1 shows that increased concentrations of the three polymers in the 
formulations increased the swelling indices, which increased proportionally with the hydra-
tion rate as the tablets’ weight increased. Formulations containing Carbomer P940 showed 
higher swelling indices than those containing CMC Na and chitosan. Swelling behaviour of 
Carbomer P940 was attributed to the uncharged -COOH group, which became hydrated, 
forming hydrogen bonds with the imbibing water and extending the polymer chain (14). The 
high water uptake by the CMC Na was due to repulsive forces of the negative charge of the 
carboxylate carried by CMC Na (-COO–Na+) (15). Relatively fair swelling characteristics of 
chitosan were primarily related to its pH-dependent solubility. Being basic in nature, chitosan 
is soluble in media with pH values lower than its pKa (approximately 6.3–6.5), leading to 
100 % ionization. While near its pKa (i.e., at pH 6.4 in distilled water), 50 % of chito san 
 molecules were ionized. The -NH3
+ group loses a proton and becomes -NH2, thus increasing 
the hydrophobicity of the hydrogel and hindering water penetration and swell ability (16, 17). 
Thus, the decreased swelling indices of chitosan may have been due either to the increased 
degree of cross-linking leading to more difficult structural expansion or a restricted water 
influx due to formation of a viscous gel layer at the tablet and mucosa contact area. 
Effects of different factors on the studied responses
The factorial design results (Table II) were analyzed individually using 2-factor inter-
action models (2FI) to describe the relationship between the response and the factors. 
Three-dimensional plots were used to screen the  influence of factors on the responses 
(Fig. 3). 
Mucoadhesive strength 
Mucoadhesive strength indicates the ability of a tablet to adhere to the buccal mucosa. 
Such prolonged adhesion enables increased absorption and the possibility of formulating 
the desired controlled-release dosage form. The extent of mucoadhesion should depend on 
the surface distribution of the polymer and the degree of swelling. Mucoadhesiveness 
 occurs first by forming a gel structure with increasing polymer chain flexibility to interact 
and entangle with the glycoprotein in the mucus and second via hydrogen bonding of the 
hydrophilic groups of the polymer with glycoproteins in the mucosal layer (18).
Mucoadhesive strength of the prepared formulations ranged from 27.67 ± 2.2 to 54.3 ± 
2.4 g (Table II). The mucoadhesive strength response was adequately modelled by R2 = 
0.983, adjusted R2 = 0.945 and predictive R2 = 0.807.
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Polymer type significantly affected the mucoadhesive strength. In the liquisol tech-
nique, CMC Na showed more pronounced mucoadhesive strength than the other poly-
mers. The higher swelling indices of CMC Na played an important role in increasing the 
mucoadhesive strength due to the presence of hydrophilic groups. Hydration of these 
functional groups resulted in water entering the polymer network, leading to polymer 
expansion. Moreover, these hydrophilic groups formed hydrogen bonds with the mucosal 
Fig. 1. Swelling indices of CIC-AZL buccoadhesive tablets using different polymers, different polymer 
concentrations and different preparation techniques; viz. SM – simple mix, LS – liquisol, WG – wet 
granulation (n = 3). Standard deviations are not shown in the figures for clarity of presentation.
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layer (19). The performance of CMC Na may be related to the good balance between the 
available hydrogen bonding sites and an open expanded conformation (20). Conversely, in 
the simple mix technique, chitosan, a cationic polymer, showed more pronounced muco-
adhesive strength than the other polymers. Mucoadhesion between chitosan and the buc-
cal mucosa at a neutral pH resulted from a series of interactions: electrostatic attraction of 
the ionized amino groups with the sialic groups of mucin and hydrogen bonding due to 
the presence of free hydroxyl groups and hydrophobic effects (21). In contrast, chitosan 
showed reduced mucoadhesive strength in the liquisol and wet granulation techniques. 
This might be highly correlated with the decreased degree of ionization of chitosan mole-
cules in both techniques. Studies have shown that the mucoadhesive properties of poly-
mers containing ionizable groups are affected by the pH of the surrounding medium. 
Hence, the pH-dependent solubility of chitosan was due to the difference between its pKa 
and the pH of the buccal mucosa (pH 6.8). Decreased ionization and chitosan aqueous 
solubility led to increased chitosan hydrophobicity and reduced cross-linking density, 
thus decreasing the degree of chitosan entanglement and electrostatic interaction with the 
mucosal layer. These results were consistent with the decreased levels in the swelling in-
dices. Carbomer’s mucoadhesive strength showed results similar to those of CMC Na due 
to the similar presence of repulsive forces of the carboxylate negative charge carried by 
both polymers. However, these similar results were statistically significant (ANOVA and 
post-hoc Least Significant Difference (LSD) test).
Increased polymer concentrations positively significantly affected mucoadhesive 
strength. Maximum values of mucoadhesive strength were attained at the highest levels of 
the three polymers. Higher concentrations may have had more penetrating chains than 
lower polymer concentrations, thus increasing the adhesive effect. For example, higher Car-
bomer concentrations upon exposure to moist surfaces lowered the microenvironmental pH, 
thus causing increased mucoadhesion. Acidic environment favors excess uncharged -COOH 
groups, which form stronger hydrogen bonds with water and strengthen the mucoadhesive 
bond. These results are consistent with those of Bertram and Bodmeier (22), who investi-
gated the effect of polymer solution concentrations used to prepare inserts on mucoadhesive 
strength. Increasing the chitosan concentration may produce more adhesive sites and poly-
mer chains for interpenetration with mucin leading to increased mucoadhesive strength.
Preparation technique had the most pronounced effect on mucoadhesive strength, 
possibly due to the difference in each polymer’s degree of hydration upon changing the 
preparation technique. Aside from chitosan, polymer molecules at the surface may be 
spaced sufficiently far apart from each other by all excipient molecules, allowing for rapid 
and complete hydration of the polymer structure, consequently producing high forces of 
adhesion following contact with the buccal mucosa (23). For chitosan, the direct and sole 
contact with Aeropril 300 (hydrophilic fumed silica) in the liquisol technique led to suc-
cessful and stable adsorption on Aeropril (24). Kocun et al. (25) investigated chitosan ad-
sorption on mica surfaces using atomic force microscopy. Images showed that the chito-
san-adsorbed films were relatively smooth with a flat conformation. These results are 
closely correlated with the chitosan-containing tablet micromeritics using the liquisol 
technique, which showed a high degree of flowability compared to its counterparts. This 
might be attributed to the formation of smooth adsorbed films on the Aeropril surface 
enhancing the tablet flow properties. Such adsorption interaction was clearly reduced in 
the simple mix and wet granulation due to other interfering excipients, which decreased 
direct contact between chitosan and Aeropril.
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In vitro release studies
The Q2 % response was adequately modelled by R2 = 0.978, adjusted R2 = 0.928 and 
predictive R2 = 0.746. The Q4 % response was adequately modelled by R2 = 0.998, adjusted 
R2 = 0.994 and predictive R2 = 0.979. The Q8 % response was adequately modelled by R2 = 
0.9996, adjusted R2 = 0.9985 and predictive R2 = 0.995. 
Dissolution profiles for all formulations are represented in Fig. 2, and the Q2 %, Q4 %, 
and Q8 % responses are shown in Table II. The drug release mechanism from swellable 
Fig. 2. In vitro release profile of CIC-AZL buccoadhesive tablets using different polymers, different 
polymer concentrations and different preparation techniques carried out in 900 mL of Sorenson phos-
phate buffer pH 6.8 at 50 r/min and 37 ± 0.5 °C containing 1 % Tween 80 (n = 6). Standard deviations 
are not shown in the figures for clarity of presentation.
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matrices could be compared via several physicochemical phenomena. Water uptake, gel 
layer formation, and polymeric chain relaxation were primarily involved in the drug 
 release modulation (14). Initial high drug release was observed in some formulations at the 
2 h time point (formulations prepared with 5 and 10 % of both CMC Na and chitosan) and 
was reduced at subsequent time points. This may have been due to the initial rapid flux of 
the drug from the particles to the dissolution medium, which was reduced with time.
Polymer type significantly affected the percentage of the drug released at different 
time intervals (2, 4, and 8 h). Tablets containing Carbomer P940 failed to control drug 
 release over the 8 h release period, since no more than 50 % of the drug was released after 
8 h from all the formulations prepared using different techniques and concentrations. This 
Fig. 3. 3D plot of AZL in CIC-AZL tablets demonstrating the effect of the studied factors on the 
 response; R1: % drug released after 2 h, R2: % drug released after 4 h, R3: % drug released after 8 h, 
and R4: mucoadhesive strength.
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could be attributed to the gelation of the matrix after the initial wetting, in addition to 
subsequent formation of more viscous gel layers on the tablet, which reduced the elution 
rate of the dissolved drug from the tablet core. Rapid AZL release from tablets containing 
CMC Na may have been due to the low viscosity (50–200 mPa s) of CMC Na, which led to 
high swellability and rapid erosion of the diffusion gel layer (26). Increasing the time led 
to sufficient hydration and polymer network swelling. Complete opening of the interpoly-
meric pores occurred indefinitely when in contact with water, eventually dissolving com-
pletely. Chitosan is soluble in acidic media, and the chitosan surface was eventually ex-
posed to a neutral pH environment (pH = 6.8) where it was rendered insoluble and thus 
showed a decreased dissolution profile compared to that of CMC Na (27).
Polymer concentration significantly negatively affected the percentage of drug released 
at different time intervals (2, 4, and 8 h), increasing the polymer concentration and retarding 
the AZL release. At lower levels, tablet hydration loosened the matrix at the surface, enabling 
water to diffuse into the core. These higher polymer levels led to significant decreases in 
drug release. This might be attributed to the increased viscosity and swellability of the gel 
layer, which slowed the erosion and increased the path that the drug had to traverse to be 
released, thus lessening its release (28). Polymers may also have had incomplete water access 
and were incompletely hydrated upon contact with the dissolution medium (23).
The preparation technique affected the release profile significantly. Tablet formula-
tions prepared using the simple mix technique failed to give the required drug amount at 
the 2, 4, 6 and 8 h time points, since no more than 50 % of the drug was released after 8 h. 
These results might be due to the presence of Poloxamer 188 in solid form in the physical 
mixture. Formulations prepared using the wet granulation technique showed the highest 
drug release for the three polymers at different concentrations, since the presence of Po-
loxamer 188 in the dissolved or melted form showed significantly enhanced dissolution 
characteristics compared to those of PMs because Poloxamer 188 increased the dissolution 
rate by combined actions of the surface activity, solubilization and wetting effect. The dis-
solution rate increased with time due to increased surface area. The liquisol technique 
showed a medium-release profile, where the presence of the drug in the dissolved form 
improved the release profile while complying with the standards of the controlled-release 
dosage form (9). These results are consistent with those of many studies that used the 
liquisol technique to enhance the solubility and dissolution of insoluble drugs (29). It is 
likely that liquisol enhancement occurred because the drug was completely dissolved in 
Poloxamer 188 in a molecularly dispersed state. Thus, the drug had an increased surface 
area available for release. At the interface between the liquisol particles and the medium, 
the liquid vehicle acts as a cosolvent, increasing the aqueous solubility of the drug. Polox-
amer 188 acted as an active surface agent improving the liquisol particle wetting. The wet 
granulation technique showed a marked increase in the dissolution profile compared to 
most liquisol formulations, possibly because the increased diffusional path length of the 
drug may paradoxically delay such release. Further, the thick gel layer formed on the swol-
len liquisol core surface can control water penetration. Diffusion of the drug through the 
swollen polymer may also be retarded because of clogged pores (30).
Kinetic analysis of the release data
The results (Table SI in Supplementary Material) showed that F#3 F#11, F#12, F#16, 
F#19, F#20, F#21, F#22, F#23, F#24, F#25, F#26 and F#27 followed zero-order kinetics, in which 
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the same amount of the drug was released per unit of time independently of drug concen-
tration. Release data from F#4 followed a diffusion-controlled mechanism as per the Higuchi 
model, while the remaining AZL formulations followed first-order kinetics. The regres-
sion coefficient of the optimized formulation (F#16) was calculated from the Hixson-Crowell 
equation. The r2 value of F#16 was approximately equal to the r2 values of the Higuchi 
 kinetics, indicating unidirectional drug release.
Determining the optimized formulation
After generating final equations relating the dependent and independent variables, 
the studied responses were optimized. Numerical optimization searched the design space 
using the final models created for each studied response to determine the levels of factors 
that met the constraints set for the different responses. F#16 prepared by the liquisol tech-
nique, containing 15 % CMC Na, was chosen with an overall desirability of 0.953. The 
value of the desirability indicates that the chosen formulations satisfied the constraints 
given in Table I. F#16, which contained 15 % CMC Na and was prepared using the liquisol 
technique, showed the highest mucoadhesive strength of 54.33 g and had the optimal re-
lease profile, in which 24.57 % of the drug was released after 2 h, 58.44 % after 4 h, and 85.44 
% after 8 h. These results complied with the required dissolution profile.
Ex vivo permeation study
AZL permeation from F#16 was slow and steady as shown in Fig. 4, where 81.44 % ± 
0.34 of AZL permeated the buccal membrane in 8 h with a flux of 0.193 mg h–1 cm–2 and 
permeability coefficient (Kp) of 0.024 cm h–1. The lag time was short (0.137 h). Successful 
increase in solubility and dissolution rate attained by the dual effects of CIC/liquisol are 
believed to be the main reasons for the increased permeation rates.
Fig. 4. Ex vivo permeation study of the optimized CIC-AZL buccoadhesive tablet (F#16 which con-
tained 15 % CMC Na prepared using the liquisol technique), carried out in 900 mL of Sorenson 
phosphate buffer pH 6.8 at 50 r/min and 37 ± 0.5 °C (n = 3).
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CONCLUSIONS
This research evaluated the key factors affecting the in vitro release studies and muco-
adhesive strength to enhance AZL bioavailability. The poor aqueous solubility and first-
pass metabolism of AZL pose the main challenges to drug delivery and were successfully 
overcome by formulating a liquisol CIC-AZL buccoadhesive tablet. The liquisol core was 
prepared and placed in CIC buccoadhesive tablets as a simple, easy, scalable and effective 
method of enhancing the dissolution profile of AZL. The ex vivo permeation study showed 
slow and steady AZL permeation. Therefore, F#16 composed of 15 % CMC Na and pre-
pared using the liquisol technique to form a CIC buccoadhesive tablet is a promising drug 
delivery system.
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